Latest Resmed Inc (RMD) Headlines Landmark Year
Post# of 39
Posted On: 03/14/2014 8:01:54 PM
Latest Resmed Inc (RMD) Headlines
Landmark Year in Sleep: Leader in Sleep and Respiratory Medicine Highlights Top Five Sleep Apnea Research Findings
PR Newswire Europe - Fri Mar 14, 11:55AM CDT
To coincide with today's World Sleep Day, ResMed , an innovator and pioneer in developing solutions for treating sleep-disordered breathing and other respiratory conditions, highlights its pick for the top five research discoveries about sleep apnea from the past year. Together, they paint an alarming picture: sleep apnea is on the rise and linked to sudden cardiac death, slower recovery from heart attacks, cancer, and high blood pressure.
The Zacks Analyst Blog Highlights:Staples, ResMed, Covidien, Stryker and SurModics
PR Newswire - Wed Mar 12, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Staples, Inc. (Nasdaq:SPLS-Free Report), ResMed, Inc. (NYSE:RMD-Free Report), Covidien plc (NYSE:COV-Free Report), Stryker Corp. (NYSE:SYK-Free Report) and SurModics, Inc. (Nasdaq:SRDX-Free Report).
Coverage Initiated on ResMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:07PM CDT
On Mar 10, 2014, we initiated coverage on ResMed, Inc.
First Time in its 25-year History, ResMed Unveils a New Brand, Reflecting Commitment to Changing Lives
PR Newswire Europe - Mon Mar 10, 7:01AM CDT
"Changing lives with every breath." That's the new tagline accompanying a refreshed ResMed brand that aligns ResMed's appearance in the marketplace with its global focus on innovation that benefits patients' lives.
Insider Trading Alert - QEP, PKG And RMD Traded By Insiders
at The Street - Wed Mar 05, 11:16AM CST
Stocks with insider trader activity include QEP, PKG and RMD
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Fri Feb 28, 7:11AM CST
ResMed (NYSE:RMD) was downgraded from Overweight to Neutral at JP Morgan today. The stock closed yesterday at $44.21 on volume of 3.2 million shares, above average daily volume of 1.3 million. In the past 52 weeks, ResMed share prices have been bracketed by a low of $41.52 and a high of $57.34 and closed yesterday at $44.21, 6% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.2% while the 200-day MA has slid 0.2%.
Insider Trading Alert - RMD, TWTC And AMP Traded By Insiders
at The Street - Fri Feb 21, 10:45AM CST
Stocks with insider trader activity include RMD, TWTC and AMP
Global Self-Care Medical Devices Market Report 2013 - Forecasts to 2019
M2 - Tue Feb 18, 11:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/r9tg99/selfcare_medical) has announced the addition of the "Global Self-Care Medical Devices Market Report 2013 - Forecasts to 2019" report to their offering. The global self-care medical devices market is estimated to be USD 10.5 billion in 2012 and is expected to reach USD 16.8 billion by 2019, growing at a CAGR of 7.0% from 2013 to 2019. Self-care medical devices are those devices that are used for measuring and monitoring various vital parameters of a patient. These devices play an important role in monitoring blood sugar level, heart rate, hypertension and other conditions. With increasing healthcare awareness, the demand for self-care medical devices is also expected to increase during the forecast period. The market for self-care medical devices is segmented as blood glucose monitors, blood pressure monitors, temperature monitors, holter monitors, pregnancy/fertility test kits, sleep apnea monitors, nebulizers and pedometers. This report also explains various technological advancements taking place in each segment. The report includes market estimations of the global self-care medical devices market in terms of value (USD million) for the period 2013 - 2019, considering 2012 as the base year. In addition, current market trends and recent developments are taken into consideration while determining the growth rate of the global self-care medical devices market. The report provides market size and forecasts for each segment and geographic region with CAGR % for the period from 2013 to 2019. Scope Segments - Blood Glucose Monitors - Blood Pressure Monitors - Body Temperature Monitors - Nebulizers - Pedometers - Pregnancy/Fertility Test Kits - Sleep Apnea Monitors - Heart Rate Monitors Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Self-Care Medical Devices Market, by Segments Chapter 5 Self-Care Medical Devices Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - 3M Healthcare - Abbott Laboratories - Bayer AG - F .Hoffmann-La Roche - GE Healthcare - Johnson & Johnson - Medtronic, Inc. - Omron Healthcare - Philips Healthcare - ResMed, Inc. For more information visit http://www.researchandmarkets.com/research/r9...re_medical
Weis Markets Announces Jonathan Weis As Its New President and Chief Executive Officer
PR Newswire - Fri Feb 14, 12:00PM CST
Weis Markets (NYSE:WMK) today announced its Board of Directors has approved Jonathan Weis as Company President and Chief Executive officer (CEO). Mr. Weis, 46, will also retain his role as Company Vice Chairman.
ResMed Earnings Review: 18 Days after Announcement Shares Down 6.8% (RMD)
Comtex SmarTrend(R) - Mon Feb 10, 7:40AM CST
18 days ago, on January 23rd, 2014, ResMed (NYSE:RMD) reported its earnings. Analysts, on average, expected earnings of $0.64 per share on sales of $398.1 million. The company actually reported EPS of $0.61 on sales of $384.3 million, missing EPS estimates by $0.03 and missing revenue estimates by $13.8 million. Shares of ResMed have slipped from $46.88 to $43.67, representing a loss of 6.8%, since the company reported earnings 18 days ago.
ResMed Shares Down 15.0% Since SmarTrend's Sell Call (RMD)
Comtex SmarTrend(R) - Tue Feb 04, 11:16AM CST
SmarTrend identified a Downtrend for ResMed (NYSE:RMD) on October 25th, 2013 at $50.20. In approximately 3 months, ResMed has returned 15.00% as of today's recent price of $42.67.
ResMed Earnings In Retrospect: Down 7.0% in the Last 11 Days (RMD)
Comtex SmarTrend(R) - Mon Feb 03, 7:00AM CST
When ResMed (NYSE:RMD) reported earnings 11 days ago on January 23rd, 2014, analysts, on average, expected the company to report earnings of $0.64 on sales of $398.1 million. ResMed actually reported earnings of $0.61 per share on sales of $384.3 million, missing EPS estimates by $0.03 and missing revenue estimates by $13.8 million. Shares of ResMed have slipped from $46.88 to $43.61, representing a loss of 7.0%, since the company reported earnings 11 days ago.
BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Jan 31, 3:15PM CST
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Fossil Group, Inc. (NDQ: FOSL) as its April 2014 "Stock to Study" and ResMed Inc. (NYSE: RMD) as its April 2014 "Undervalued Stock" for investors' informational and educational use.
AMCP: Proposed Part D Changes Could Undermine Program
PR Newswire - Thu Jan 30, 8:00AM CST
Overdue Change in Protected Classes Overshadowed by Parts Impacting Cost and Access for Beneficiaries
Shares of RMD Down 12.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 28, 10:02AM CST
SmarTrend identified a Downtrend for ResMed (NYSE:RMD) on October 25th, 2013 at $50.20. In approximately 3 months, ResMed has returned 12.53% as of today's recent price of $43.91.
ResMed Misses on Q2FY14 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 8:20AM CST
ResMed Inc. reported second-quarter fiscal 2014 (ended Dec 31, 2013) adjusted earnings per share of 60 cents.
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended Dec. 31, 2013
PR Newswire - Thu Jan 23, 3:05PM CST
ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended Dec. 31, 2013. Revenue for the quarter ended Dec. 31, 2013 was $384.3 million, a 2 percent increase (a 1 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. For the quarter ended Dec. 31, 2013, net income was $86.6 million, an increase of 11 percent compared to the quarter ended Dec. 31, 2012. Diluted earnings per share for the quarter ended Dec. 31, 2013 were $0.60, an increase of 13 percent compared to the quarter ended Dec. 31, 2012.
Landmark Year in Sleep: Leader in Sleep and Respiratory Medicine Highlights Top Five Sleep Apnea Research Findings
PR Newswire Europe - Fri Mar 14, 11:55AM CDT
To coincide with today's World Sleep Day, ResMed , an innovator and pioneer in developing solutions for treating sleep-disordered breathing and other respiratory conditions, highlights its pick for the top five research discoveries about sleep apnea from the past year. Together, they paint an alarming picture: sleep apnea is on the rise and linked to sudden cardiac death, slower recovery from heart attacks, cancer, and high blood pressure.
The Zacks Analyst Blog Highlights:Staples, ResMed, Covidien, Stryker and SurModics
PR Newswire - Wed Mar 12, 8:30AM CDT
Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the Staples, Inc. (Nasdaq:SPLS-Free Report), ResMed, Inc. (NYSE:RMD-Free Report), Covidien plc (NYSE:COV-Free Report), Stryker Corp. (NYSE:SYK-Free Report) and SurModics, Inc. (Nasdaq:SRDX-Free Report).
Coverage Initiated on ResMed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 3:07PM CDT
On Mar 10, 2014, we initiated coverage on ResMed, Inc.
First Time in its 25-year History, ResMed Unveils a New Brand, Reflecting Commitment to Changing Lives
PR Newswire Europe - Mon Mar 10, 7:01AM CDT
"Changing lives with every breath." That's the new tagline accompanying a refreshed ResMed brand that aligns ResMed's appearance in the marketplace with its global focus on innovation that benefits patients' lives.
Insider Trading Alert - QEP, PKG And RMD Traded By Insiders
at The Street - Wed Mar 05, 11:16AM CST
Stocks with insider trader activity include QEP, PKG and RMD
Downgrade Alert for ResMed (RMD)
Comtex SmarTrend(R) - Fri Feb 28, 7:11AM CST
ResMed (NYSE:RMD) was downgraded from Overweight to Neutral at JP Morgan today. The stock closed yesterday at $44.21 on volume of 3.2 million shares, above average daily volume of 1.3 million. In the past 52 weeks, ResMed share prices have been bracketed by a low of $41.52 and a high of $57.34 and closed yesterday at $44.21, 6% above that low price. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.2% while the 200-day MA has slid 0.2%.
Insider Trading Alert - RMD, TWTC And AMP Traded By Insiders
at The Street - Fri Feb 21, 10:45AM CST
Stocks with insider trader activity include RMD, TWTC and AMP
Global Self-Care Medical Devices Market Report 2013 - Forecasts to 2019
M2 - Tue Feb 18, 11:14AM CST
Research and Markets (http://www.researchandmarkets.com/research/r9tg99/selfcare_medical) has announced the addition of the "Global Self-Care Medical Devices Market Report 2013 - Forecasts to 2019" report to their offering. The global self-care medical devices market is estimated to be USD 10.5 billion in 2012 and is expected to reach USD 16.8 billion by 2019, growing at a CAGR of 7.0% from 2013 to 2019. Self-care medical devices are those devices that are used for measuring and monitoring various vital parameters of a patient. These devices play an important role in monitoring blood sugar level, heart rate, hypertension and other conditions. With increasing healthcare awareness, the demand for self-care medical devices is also expected to increase during the forecast period. The market for self-care medical devices is segmented as blood glucose monitors, blood pressure monitors, temperature monitors, holter monitors, pregnancy/fertility test kits, sleep apnea monitors, nebulizers and pedometers. This report also explains various technological advancements taking place in each segment. The report includes market estimations of the global self-care medical devices market in terms of value (USD million) for the period 2013 - 2019, considering 2012 as the base year. In addition, current market trends and recent developments are taken into consideration while determining the growth rate of the global self-care medical devices market. The report provides market size and forecasts for each segment and geographic region with CAGR % for the period from 2013 to 2019. Scope Segments - Blood Glucose Monitors - Blood Pressure Monitors - Body Temperature Monitors - Nebulizers - Pedometers - Pregnancy/Fertility Test Kits - Sleep Apnea Monitors - Heart Rate Monitors Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Self-Care Medical Devices Market, by Segments Chapter 5 Self-Care Medical Devices Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - 3M Healthcare - Abbott Laboratories - Bayer AG - F .Hoffmann-La Roche - GE Healthcare - Johnson & Johnson - Medtronic, Inc. - Omron Healthcare - Philips Healthcare - ResMed, Inc. For more information visit http://www.researchandmarkets.com/research/r9...re_medical
Weis Markets Announces Jonathan Weis As Its New President and Chief Executive Officer
PR Newswire - Fri Feb 14, 12:00PM CST
Weis Markets (NYSE:WMK) today announced its Board of Directors has approved Jonathan Weis as Company President and Chief Executive officer (CEO). Mr. Weis, 46, will also retain his role as Company Vice Chairman.
ResMed Earnings Review: 18 Days after Announcement Shares Down 6.8% (RMD)
Comtex SmarTrend(R) - Mon Feb 10, 7:40AM CST
18 days ago, on January 23rd, 2014, ResMed (NYSE:RMD) reported its earnings. Analysts, on average, expected earnings of $0.64 per share on sales of $398.1 million. The company actually reported EPS of $0.61 on sales of $384.3 million, missing EPS estimates by $0.03 and missing revenue estimates by $13.8 million. Shares of ResMed have slipped from $46.88 to $43.67, representing a loss of 6.8%, since the company reported earnings 18 days ago.
ResMed Shares Down 15.0% Since SmarTrend's Sell Call (RMD)
Comtex SmarTrend(R) - Tue Feb 04, 11:16AM CST
SmarTrend identified a Downtrend for ResMed (NYSE:RMD) on October 25th, 2013 at $50.20. In approximately 3 months, ResMed has returned 15.00% as of today's recent price of $42.67.
ResMed Earnings In Retrospect: Down 7.0% in the Last 11 Days (RMD)
Comtex SmarTrend(R) - Mon Feb 03, 7:00AM CST
When ResMed (NYSE:RMD) reported earnings 11 days ago on January 23rd, 2014, analysts, on average, expected the company to report earnings of $0.64 on sales of $398.1 million. ResMed actually reported earnings of $0.61 per share on sales of $384.3 million, missing EPS estimates by $0.03 and missing revenue estimates by $13.8 million. Shares of ResMed have slipped from $46.88 to $43.61, representing a loss of 7.0%, since the company reported earnings 11 days ago.
BetterInvesting Magazine Releases April Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Jan 31, 3:15PM CST
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Fossil Group, Inc. (NDQ: FOSL) as its April 2014 "Stock to Study" and ResMed Inc. (NYSE: RMD) as its April 2014 "Undervalued Stock" for investors' informational and educational use.
AMCP: Proposed Part D Changes Could Undermine Program
PR Newswire - Thu Jan 30, 8:00AM CST
Overdue Change in Protected Classes Overshadowed by Parts Impacting Cost and Access for Beneficiaries
Shares of RMD Down 12.5% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Tue Jan 28, 10:02AM CST
SmarTrend identified a Downtrend for ResMed (NYSE:RMD) on October 25th, 2013 at $50.20. In approximately 3 months, ResMed has returned 12.53% as of today's recent price of $43.91.
ResMed Misses on Q2FY14 Earnings, Revs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jan 27, 8:20AM CST
ResMed Inc. reported second-quarter fiscal 2014 (ended Dec 31, 2013) adjusted earnings per share of 60 cents.
ResMed Inc. Announces Record Financial Results For The Quarter Ended And Six Months Ended Dec. 31, 2013
PR Newswire - Thu Jan 23, 3:05PM CST
ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended Dec. 31, 2013. Revenue for the quarter ended Dec. 31, 2013 was $384.3 million, a 2 percent increase (a 1 percent increase on a constant currency basis) over the quarter ended Dec. 31, 2012. For the quarter ended Dec. 31, 2013, net income was $86.6 million, an increase of 11 percent compared to the quarter ended Dec. 31, 2012. Diluted earnings per share for the quarter ended Dec. 31, 2013 were $0.60, an increase of 13 percent compared to the quarter ended Dec. 31, 2012.
(0)
(0)